Debt to Equity Ratio Chart

View Debt to Equity Ratio for OMER.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2009. Start Trial.
Date Value
June 30, 2026 -5.781
March 31, 2026 -4.905
December 31, 2025 -3.357
September 30, 2025 -1.648
June 30, 2025 -1.670
March 31, 2025 -1.944
December 31, 2024 -2.318
September 30, 2024 -2.811
June 30, 2024 -3.566
March 31, 2024 -6.619
December 31, 2023 -14.47
September 30, 2023 -33.42
June 30, 2023 22.77
March 31, 2023 8.510
December 31, 2022 5.465
September 30, 2022 -10.10
June 30, 2022 -10.49
March 31, 2022 -69.47
December 31, 2021 14.63
September 30, 2021 -1.326
June 30, 2021 -1.416
March 31, 2021 -1.549
December 31, 2020 -2.195
September 30, 2020 -3.049
June 30, 2020 -1.225
Date Value
March 31, 2020 -1.484
December 31, 2019 -1.780
September 30, 2019 -1.34
June 30, 2019 -1.397
March 31, 2019 -1.49
December 31, 2018 -1.512
September 30, 2018 -1.486
June 30, 2018 -2.316
March 31, 2018 -2.928
December 31, 2017 -30.07
September 30, 2017 9.027
June 30, 2017 -1.491
March 31, 2017 -1.678
December 31, 2016 -2.129
September 30, 2016 -3.095
June 30, 2016 -1.429
March 31, 2016 -1.228
December 31, 2015 -1.900
September 30, 2015 -3.171
June 30, 2015 3.879
March 31, 2015 1.507
December 31, 2014 -0.7668
September 30, 2014 -1.224
June 30, 2014 -3.051
March 31, 2014 6.180

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Eli Lilly & Co. 1.621
Talphera, Inc. 0.4511
Hyperion DeFi, Inc. 0.0874
ANI Pharmaceuticals, Inc. 1.022
Corcept Therapeutics, Inc. 0.0133